OBJECTIVES: Re-hospitalization and mortality rates are increasingly being used as quality of care measures that have significant reimbursement implications. We examine the rates of re-hospitalization and mortality of acute coronary syndrome (ACS) patients in real-world clinical practice. METHODS: Commercially-insured patients (age Ͼ18 years) with an inpatient hospitalization for ACS [ICD-9-CM codes for acute myocardial infarction or unstable angina (UA)] between 1/1/2007-5/31/ 2010 were identified from medical claims in the HealthCore Integrated Research Database (HIRD). Patients with ACS events within one year prior to index hospitalization were excluded. All-cause and ACS-related re-hospitalizations and mortality rates within 30 days and 12 months after index event were evaluated. RESULTS: Of 66,772 ACS patients (60% male; mean age 66.6 years), 21% had diagnostic coding for ST elevation myocardial infarction (STEMI), 31% had coding for non-ST elevation myocardial infarction (NSTEMI), 37% had UA, and 11% had not otherwise specified (NOS) ACS. Approximately, 90% and 52% of patients had Ͼ30-days and Ͼ 12 months of continuous eligibility respectively. The 30-day all-cause re-hospitalization rate was 16.3 % (STEMI: 16.4%, NSTEMI: 19.0%, UA: 13.3%, NOS: 20.6%;) and 6.3 % (STEMI: 8.8%, NSTEMI: 6.6%, UA: 5.2%, NOS: 4.5%) for an ACS-related re-hospitalization. The 12-month all cause re-hospitalization rate was 41.3% (STEMI: 39.0%, NSTEMI: 46.4%, UA: 38.2%NOS: 46.6%, )and 16.6% for an ACS-related re-hospitalization. The 30-day post-index mortality rate was 2.4 % (STEMI:1 .8%, NSTEMI:4.3%, UA:0.5%, NOS:5.2%;) and the 12-month rate was 7.0%. For patients with ages Ͼ 65 years, the 30-day all-cause and ACS-related re-hospitalization rates were 21.2% and 7.0%, respectively. CONCLUSIONS: The re-hospitalization and mortality rate for ACS patients within 30 days and 12-months post-index hospitalization discharge as observed in real-world clinical practice remain high. Use of more effective therapies may provide an opportunity to improve important clinical and economic outcomes in ACS patients.
OBJECTIVES:
Cost-effectiveness analysis is now well established in relation to the evaluation of health technologies, but not in relation to broader institutional level variations in clinical pathways. Linked, routinely collected data provides an opportunity to evaluate real world activity. A novel approach to analysing the risk-adjusted cost-effectiveness (RAC-E) of acute services for patients presenting with chest pain at the four main public hospitals in South Australia is presented. METHODS: Routinely collected data on hospital separations (including costs) and mortality records were linked deterministically. Relevant intermediate endpoints over a two year follow-up period in a cohort of patients presenting with chest pain in the year to July 2006 were identified. Lifetime costs and survival were extrapolated from these endpoints using data from chest pain patients presenting between July 2002 and June 2008. The resulting estimates of costs and survival were standardized using separate regression models that estimated expected cost and survival values for each patient. RESULTS: In the base case, two of the four hospitals were dominated by hospital 1. Hospital 2 had lower standardized lifetime costs than hospital 1, and the incremental cost per life year gained between these two hospitals was Aus$2,909. A bootstrapped probabilistic sensitivity analysis showed hospital 1 to have very high probabilities of cost-effectiveness at relevant dollar values for a life year gained. Analysis of differences in cost components between the hospitals showed that hospital 1 spent relatively less on pathology and imaging, whilst spending more on nursing time and pharmaceuticals. CONCLUSIONS: RAC-E provides a useful framework for identifying important differences in the costs and benefits associated with variations in clinical practice. Potential determinants can be partially investigated with the data, but further primary analysis of clinical pathways at key hospitals is required to fully inform the dissemination of best practice. 
PCV108 CARDIOVERSION TREATMENT PATTERNS AND OUTCOMES AMONG ACUTE ATRIAL FIBRILLATION PATIENTS IN 5 EUROPEAN COUNTRIES

OBJECTIVES:
We examine current treatment patterns associated with the use of antiarrhythmics for pharmacologic cardioversion and evaluate time to conversion among patients with acute atrial fibrillation (AF) in France, Italy, Germany, Spain, and UK. METHODS: Data were collected cross-sectionally as observed by 303 physicians from April to June 2010. RESULTS: Among 2,997 patients, 1,352 (45%) received pharmacologic cardioversion only, with 1,082 (80%) successfully cardioverting. Of these, 931 (69% of those treated pharmacologically, 86% of those successfully) had complete information on time to achieve sinus rhythm and were further assessed here. Amiodarone was administered to most (49%), with similar proportions receiving intravenous (IV) (53%) and oral (46%) formulations. Amioda-rone IV was associated with a significantly shorter median conversion time (8 hours) compared to oral (36 hours). Patients treated with flecainide (26%) had the shortest median time to cardioversion (4 hours), while patients on propafenone (15%) were next (6 hours). Median cardioversion time varied by country. Specifically, patients in France took longer to convert on amiodarone IV and oral at a median time of 12 and 48 hours compared to an average of 7 and 24 hours, respectively, in other countries. In Germany, little difference was observed with median conversion times of 9 and 10 hours for amiodarone IV and oral, respectively. Median conversion times were also similar between amiodarone IV and flecainide in Spain and Italy (a difference of 1 and 2 hours, respectively) compared to an average difference in median conversion time of 4 hours between these treatments overall. CONCLUSIONS: While amiodarone had a longer median time to cardioversion, faster acting agents, such as flecainide and propafenone, had conversion times substantially longer than their known time of action, reflecting other influences on treatment administration. Differences in conversion time suggest country-and physician-specific practices in the use of pharmacologic cardioversion therapies. OBJECTIVES: Epidemiological models have been widely used to estimate how increased uptakes of medical and surgical treatments affect mortality and related outcomes. Standard methods rely on the estimate of the case fatality, defined as the risk of death in the absence of the treatment. Because most patients receive some treatment, mortality rates where some treatment is present are often used instead of case fatality rates, leading to biased results. A method that does not rely on case fatality estimates is needed. METHODS: We borrow the mechanism used for the calculation of the Potent Impact Fraction (PIF), an epidemiological measure that is equal to the proportional reduction in the incidence of a disease or mortality, resulting from a specific change in the distribution of a risk factor in the population, and apply it to the estimation of the relative reduction of mortality caused by the increase of treatment uptake in the population at risk. We apply this method to estimate the reduction of cardiovascular disease deaths in Ontario, if treatment rates for CHD interventions were to be increased from 2005 levels to the recommended benchmark utilization of 90%. The Mant-Hicks model for polypharmacy is adopted, while the uptakes of multiple treatments are assumed to be independent from each other. RESULTS: Using the proposed PIF-based method, we estimated that increasing treatment to benchmark levels uptake results in a reduction of cardiovascular mortality of 22.5%. The standard method gives a reduction of 17%, probably due to underestimation of the case fatality. CONCLUSIONS: Here we present an alternative method for the estimation of the effect of treatment uptake increase to the reduction of mortality. Our example suggests that the magnitude of bias associated with the standard method may be substantial. This approach may be a useful tool for epidemiological and health care research.
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PCV109 BEYOND CASE FATALITY: A NEW METHOD TO ESTIMATE THE EFFECT OF INCREASING TREATMENT UPTAKE ON MORTALITY
PCV110 DEVELOPMENT AND VALIDATION OF A SHORT PRO MEASURE OF HEALTH STATUS FOR INDIVIDUALS WITH ACUTE MYOCARDIAL INFARCTION: THE MYOCARDIAL INFARCTION DIMENSIONAL ASSESSMENT SCALE (MIDAS)
OBJECTIVES: To develop and validate a disease-specific health status measure for individuals with myocardial infarction (MI). METHODS: The development of the Myocardial Infarction Dimensional Assessment Scale (MIDAS) followed three main stages. Stage 1 consisted of in-depth, semi-structured, exploratory interviews conducted on a sample of 31 patients to identify areas of salience and concern to patients with MI. These interviews generated 48 candidate questions. In stage 2 the 48-item questionnaire was used in a postal survey to identify appropriate rephrasing/shortening, to determine acceptability and to help identify sub-scales of the instrument addressing different dimensions of MI. Finally, in stage 3 the construct validity of MIDAS subscales was examined in relation to clinical and other health outcomes. Setting -A single centre (district general hospital) in England was used for stages 1 and 3 and a national postal survey was conducted for stage 2. Patients -A total of 410 patients were recruited for the national survey (stage 2). Full data was available on 348 (85%) patients. 155 patients were recruited to test construct validity (stage 3). RESULTS: The MIDAS contains 35 questions measuring seven areas of health status: physical activity, insecurity, emotional reaction, dependency, diet, concerns over medication and side effects. The measure has high face, internal and construct validity and is likely to prove useful in the evaluation of treatment regimes for MI. CONCLUSIONS: The MIDAS has acceptable validity and reliability. It is suitable for use in a variety of settings for patients with myocardial infarction.
PCV111
IDENTIFICATION OF RESPONSE SHIFT AMONG HYPERTENSIVE PATIENTS WITH CORONARY ARTERY DISEASE USING TWO STRUCTURAL EQUATION MODELING TECHNIQUES
